Sponsors
The bill aims to strengthen U.S. PPE supply chains and support domestic manufacturers to improve emergency access and preparedness, at the trade-off of higher potential costs for taxpayers and agencies, added bureaucracy, and some risk of procurement delays that could affect frontline workers during rapid public-health crises.
Healthcare workers and hospitals will have more reliable access to certified PPE during declared public-health emergencies because the program guarantees production capacity and maintains a vetted list of FDA 510(k)-cleared PPE at set benchmarks.
Domestic PPE manufacturers will gain predictable federal demand through prioritized purchasing, supporting U.S. manufacturing jobs and investment.
Taxpayers receive price protections because products on the qualified list must use Secretary-established fair-market benchmarks, limiting overpayment for guaranteed purchases.
Taxpayers and public agencies could face higher costs if U.S.-made PPE is more expensive, guaranteed contracts exceed need, or fair-market benchmarks are set too high.
Healthcare workers and hospitals may experience slower access to suitable PPE during fast-moving emergencies because strict FDA 510(k) clearance requirements, CDC/OSHA standards, and aggressive domestic sourcing timelines can delay or exclude alternative suppliers.
Smaller or foreign-owned manufacturers may be excluded from federal contracts, reducing supplier competition and potentially increasing long-term prices and harming small businesses.
Based on analysis of 4 sections of legislative text.
Requires HHS to contract with U.S. PPE manufacturers, restricts federal-funded PPE purchases to U.S.-made items (with narrow exceptions), and mandates a report on PPE policy changes and impacts.
Introduced January 23, 2025 by H. Morgan Griffith · Last progress January 23, 2025
Creates a federal program to partner with and contract domestic manufacturers to guarantee availability of qualified personal protective equipment (PPE) for public health emergencies, sets progressive domestic-production thresholds and product-quality requirements, and maintains a list of approved PPE. Bars federal, state, and local agencies from using federal funds to buy PPE made outside the United States (with narrow statutory exceptions and documentation requirements). Requires HHS to finalize the partnership contracting process within one year and to report to Congress on PPE regulatory changes and effects on in-person medical staff safety during 2020–2021 within one year.